With an extensive presence in North America, Europe, South America, Australia, New Zealand, South Africa and more recently in the MENA region, Accord Healthcare has very rapidly become one of the fastest growing generic pharmaceutical companies. With a robust product portfolio in growth oriented therapies, such as Oncology, Cardiology, Neurology, Nephrology, Urology, Psychiatry, Diabetology, Pain management and Gastroenterology and over 4000 product approvals in various markets, Accord’s sales, marketing and distribution network now reaches over 60 countries.
Our North America and European operations were started with a strategic vision to create a global brand in the world’s largest pharmaceutical markets, supported by a commercial infrastructure that enables us to bring our high quality yet affordable products to patients.
Our large and growing portfolio allows us to compete with some of the biggest portfolios in the industry as well as helps to extend our presence into new markets.
Accord is committed to uncompromised quality for its products and services across the globe. Our products are manufactured under the highest international standards and our manufacturing plants are approved by major global regulatory agencies such as the USFDA and MHRA.
Accord upholds modern R+D and manufacturing facilities in Europe, North America and Asia. Our infrastructure includes oncology and non-oncology parental development in addition to a wide range of solid formulation development capabilities. Our development laboratories are equipped with modern and sophisticated tools to support analytical challenges and meet required quality levels.
In the last 4 years, the group has acquired 3 CROs, in North America and the EU, and now undertakes clinical research simultaneously across 3 continents.
In total, these sites comprise over 617 beds and have their own dedicated Clinical and Bio analytical laboratories.
Accord has completed, nearly 5000 clinical trials ranging from Phase I – IV and Bioequivalence studies. Additionally, various pharmacovigilance services can be provided in accordance with the European PV obligations.
The organisation now has over 550 clinical research employees and has supported over 500 submissions in USA, EU, Canada and Australia.
At Accord, we constantly endeavour to deliver high quality yet affordable medicines to patients all over the world. To achieve our objective of addressing the unmet medical needs and providing access to quality and affordable medicines, we are constantly looking for partnering opportunities. We believe in strong and long-term relationships that are of mutual benefit to both Accord and its partner
At Accord Healthcare, we always look for an opportunity to serve the patient community. One of our key strategies is to in-license molecules that are synergistic to our existing portfolio enabling a wider choice to the patients. In return, our vast sales and distribution network provides ready market access to our partner. We approach In-licensing with an open mind and are flexible on the business model, from straight product supply to technology transfer to profit sharing. We are also interested in In-licensing opportunities for value-add products such as those with Novel/New Drug Delivery Systems.
At Accord, we are always open to exploring co-marketing opportunities to increase the market exposure. Leveraging on each other’s strengths and to be able to reach out to a larger patient population is our mantra for co-marketing. For a partner, on the one hand Accord offers an extensive portfolio of products and on the other a very vast and growing market reach.
With an extensive portfolio, particularly in oral solids, Accord healthcare would be pleased to discuss out-licensing opportunities within the Canadian market.
If you wish to explore any other business ideas or opportunities, we would be glad to hear from you.
For any business development related query or opportunity please contact Michel Roy at firstname.lastname@example.org.